D.E. Shaw & Co’s Generate Biomedicines GENB Stock Holding History

D.E. Shaw & Co’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-95,000	Closed	-$1.19M	–	5354
2026 Q1	$1.19M	Buy	+95,000	New	+$1.16M	﹤0.01%	3319

Other funds holding GENB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

D.E. Shaw & Co's GENB Position: Q2 2026 in Review

D.E. Shaw & Co sold out of Generate Biomedicines (GENB) in Q2 2026, closing a stake of 95,000 shares — an estimated $1.19M sold.

D.E. Shaw & Co first reported a position in GENB in Q1 2026 and held it in 1 quarter. The position peaked at $1.19M in Q1 2026. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

D.E. Shaw & Co reported no remaining Generate Biomedicines position as of Q2 2026 after selling out during the quarter.
D.E. Shaw & Co sold 95,000 Generate Biomedicines shares in Q2 2026, an estimated $1.19M.
D.E. Shaw & Co first reported a position in Generate Biomedicines in Q1 2026 and held it in 1 quarter.
D.E. Shaw & Co's Generate Biomedicines position peaked at $1.19M in Q1 2026.
86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.